Sectors & IndustriesHealthcareDiagnostics & Research

Best Diagnostic & Research Stocks to Buy Now (2025)

Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

Fonar (NASDAQ:FONR) is the #1 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Fonar (NASDAQ:FONR) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: C, and AI: C.

Fonar (NASDAQ:FONR) has a Due Diligence Score of 39, which is 13 points higher than the diagnostic & research industry average of 26.

FONR passed 11 out of 33 due diligence checks and has average fundamentals. Fonar has seen its stock lose -6.88% over the past year, overperforming other diagnostic & research stocks by 20 percentage points.

Sotera Health Co (NASDAQ:SHC) is the #2 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: A, Momentum: C, Sentiment: B, Safety: A, Financials: C, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 20, which is -6 points lower than the diagnostic & research industry average of 26. Although this number is below the industry average, our proven quant model rates SHC as a "A".

SHC passed 7 out of 33 due diligence checks and has weak fundamentals. Sotera Health Co has seen its stock return 5.54% over the past year, overperforming other diagnostic & research stocks by 32 percentage points.

Sotera Health Co has an average 1 year price target of $14.33, a downside of -12.44% from Sotera Health Co's current stock price of $16.37.

Sotera Health Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Sotera Health Co, 66.67% have issued a Strong Buy rating, 0% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Charles River Laboratories International (NYSE:CRL) is the #3 top diagnostic & research stock out of 56 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Charles River Laboratories International (NYSE:CRL) is: Value: C, Growth: B, Momentum: D, Sentiment: B, Safety: B, Financials: B, and AI: B.

Charles River Laboratories International (NYSE:CRL) has a Due Diligence Score of 14, which is -12 points lower than the diagnostic & research industry average of 26. Although this number is below the industry average, our proven quant model rates CRL as a "B".

CRL passed 4 out of 33 due diligence checks and has weak fundamentals. Charles River Laboratories International has seen its stock lose -18.05% over the past year, overperforming other diagnostic & research stocks by 9 percentage points.

Charles River Laboratories International has an average 1 year price target of $170.25, an upside of 4.25% from Charles River Laboratories International's current stock price of $163.31.

Charles River Laboratories International stock has a consensus Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Charles River Laboratories International, 25% have issued a Strong Buy rating, 12.5% have issued a Buy, 62.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.29%, which is 1 percentage points higher than the diagnostic & research industry average of 0.61%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 36.6% indicates that its dividend yield is sustainable for the long-term.

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.78%, which is the same as the diagnostic & research industry average of 0.61%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 31.5% indicates that its dividend yield is sustainable for the long-term.

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.58%, which is the same as the diagnostic & research industry average of 0.61%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 22.9% indicates that its dividend yield is sustainable for the long-term.

Diagnostic & research stocks were up 0.89% in the last day, and down -0.15% over the last week. Neogenomics was the among the top gainers in the diagnostics & research industry, gaining 21.78% yesterday.

NeoGenomics shares are trading higher after the company announced that the District Court for the Middle District of North Carolina has granted motion for summary judgement that all of Natera's asserted patent claims are invalid for claiming ineligible subject matter.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 43, which is 28 points higher than the diagnostic & research industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Icon's stock has dropped -44.49% in the past year. It has underperformed other stocks in the diagnostic & research industry by -18 percentage points.

Fonar (NASDAQ:FONR) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Fonar has a valuation score of 71, which is 56 points higher than the diagnostic & research industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has dropped -6.88% in the past year. It has overperformed other stocks in the diagnostic & research industry by 20 percentage points.

Qiagen Nv (NYSE:QGEN) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 29, which is 14 points higher than the diagnostic & research industry average of 15. It passed 2 out of 7 valuation due diligence checks.

Qiagen Nv's stock has gained 1.8% in the past year. It has overperformed other stocks in the diagnostic & research industry by 29 percentage points.

55% of diagnostic & research stocks rated by analysts are a buy right now. On average, analysts expect diagnostic & research stocks to rise by 6.8% over the next year.

4.88% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 19.51% of diagnostic & research stocks are rated B (Buy), 58.54% are rated C (Hold), 12.2% are rated D (Sell), and 4.88% are rated F (Strong Sell).